Trial Profile
A randomized, double-blind, placebo-controlled study of ATI-2042 in patients with paroxysmal atrial fibrillation and pacemakers with atrial fibrillation data logging capabilities.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2012
Price :
$35
*
At a glance
- Drugs Budiodarone (Primary)
- Indications Paroxysmal atrial fibrillation
- Focus Therapeutic Use
- Acronyms PASCAL
- Sponsors ARYx Therapeutics
- 29 Aug 2012 Results presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
- 29 Aug 2012 Patient numbers changed from 110 to 72 as reported in the abstract
- 14 Nov 2009 Results have been published as an abstract in the proceedings of the 82nd Annual Scientific Sessions of the American Heart Association (AHA) 2009.